Want to join the conversation?
$EMR remains focused on the completion of both the restructuring programs and strategic portfolio repositioning activities that were initiated in the prior year. $EMR's long-standing commitment to return cash flow to its shareholders will be supported by an expected increase in operating cash flow in FY16 to about $3Bil.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)